Clin Osteol 2009; 14(1): 15-19

Ibandronate in the treatment of postmenopausal osteoporosis: one drug, two optionsReview articles

T. Hála

Published: June 11, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hála T. Ibandronate in the treatment of postmenopausal osteoporosis: one drug, two options. Osteologický bulletin. 2009;14(1):15-19.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adami S., Viapiana O. Ibandronate Drugs of today, 2003;39(11):877-886. Go to original source...
    2. Epstein S., Zaidi M. Biological properties and mechanism of action of ibandro te: Aplication to the treatment of osteoporosis. Bone, 2005;37(4):433-40. Go to original source...
    3. Rocker R. R., Stakkestad J. A, Felsenberg D. et al. A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial. Osteoporos Int, 2000;11:S209.
    4. Adami S., Schimmer R., Coutant K. et al. Three-monthly 2 mg intravenous iban­ dronate injections restore 2002;13:S14 (abstract O36).
    5. Delmas P. D., Adami S., Strugala C. et al. Intravenous ibandronate injection postmenopausal women with osteoporosis: one-year results from the dosing intra­ venous administration study. Arthritis Rheum, 2006;54(6):1838-1846. Go to original source...
    6. Eisman J. A., Civitelli R., Adami S. et al. Efficacy and tolerability of intraven ibandronate injections in postmenopausal osteoporosis: 2-years result from the DI­ VA study. J Rheumatol, 2008;35(3):488^97.
    7. Bianchi G., Sambrook P. N., Lewiecky E. M. et al. Low incidence of flu-like ill­ ness with intravenous ibandronate injections: DIVA 2-year results. Poster 788 Eular 2006.
    8. Chesnut III. Ch., Skag A, Christiansen C. et al. Effect of oral ibandronate admi­ nistered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004;19:1241-1249. Go to original source...
    9. Rocker R., Stakkestad J. A., Weber T. et al. Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval: Results from a pivotal phase III study in postmenopausal osteoporosis. 24th ASBMR (September 20-24, San Antonio,Texas). J Bone Miner Res, 2002;17:S134 Abstr. 1038.
    10. Ettinger M. P., Felsenberg D., Hartus S. T. et al. Safety and tolerability of oral ily and intermittent ibandronate are not influenced by age. J Rheumatol, 2005; 32 (10): 1968-1974.
    11. Reginster J. Y., Wilson K. M., Dumont E. et al. Monthly oral ibandonate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab, 2005;90(0):5018-24. Go to original source...
    12. Miller P. D., McClung M. R., Macovei L. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res,2005;20:1315-22. Go to original source...
    13. Stakkestad J. A, Lakatos P., Lorenc R. et al. Monthly oral ibandronate is effecti­ ve and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol, 2008;27:955-960. Go to original source...
    14. Miller P. D., Epstein S., Sedarati F. et al. Once-monthly oral ibandronate compa­ red with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res, 2008;24 (1):207-213. Go to original source...
    15. Cranney A, Wells G. A., Yetisir E. et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient date. Osteoporos Int. 2008; [Epub ahead of print] Go to original source...
    16. Harris S. T., Blumentals W. A., Miller P. D. Ibandronate and the risk of nonvertebral and clinical fractures in women with postmenopausal osteoporosis: results of a metaanalysis of phases III studies. Curr Med Res, 2008;24(1):237-245. Go to original source...
    17. Reginster J. Y., Barr C. E., Blumentals W. A. et al. Similar non-vertebral ture efficacy demostrated with monthly ibandronate versus weekly bisphosphona­ te therapy: a retrospective cohort study. Ann Rheum Dis, 2008;67(suppl II):539.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.